高效液相色谱荧光法测定血浆中左氧氟沙星的浓度及其生物等效性研究

杨小英; 张文萍; 王欣瑜; 党宏万

doi:10.3969/j.issn.1006-0111.2016.05.012

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

x 关闭永久关闭

《药学实践与服务》杂志目前不收取审稿费、版面费、加急费等费用，如收到邮件声称是编辑部X编辑，要求加作者微信的，请谨防财产损失！编辑部用于作者校对时绑定微信的邮件通过yxsjzzs@163.com发送，标题是《药学实践与服务》XML数字出版服务微信绑定，请区分开。

高效液相色谱荧光法测定血浆中左氧氟沙星的浓度及其生物等效性研究

杨小英, 张文萍, 王欣瑜, 党宏万

文章导航 > 药学实践与服务 > 2016 > 34(5): 428-430,440

杨小英, 张文萍, 王欣瑜, 党宏万. 高效液相色谱荧光法测定血浆中左氧氟沙星的浓度及其生物等效性研究[J]. 药学实践与服务, 2016, 34(5): 428-430,440. doi: 10.3969/j.issn.1006-0111.2016.05.012

引用本文:

ZHU Hengmei, LU Guihua, FANG Shuheng, XU Lili. Pain Management with fentanyl transdermal and morphine subcutaneous injection for the patients with advanced liver cancer pain after intervention therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(1): 75-77. doi: 10.3969/j.issn.1006-0111.2017.01.019

Citation:

YANG Xiaoying, ZHANG Wenping, WANG Xinyu, DANG Hongwan. Determination of levofloxacin concentration in plasma of Chinese healthy volunteers by HPLC with fluorescence detection and bioequivalence study of levofloxacin hydrochloride tablets[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(5): 428-430,440. doi: 10.3969/j.issn.1006-0111.2016.05.012

高效液相色谱荧光法测定血浆中左氧氟沙星的浓度及其生物等效性研究

doi: 10.3969/j.issn.1006-0111.2016.05.012

宁夏医科大学总医院, 药剂科, 宁夏银川 750004;宁夏医科大学总医院, 临床药理研究室, 宁夏银川 750004

Determination of levofloxacin concentration in plasma of Chinese healthy volunteers by HPLC with fluorescence detection and bioequivalence study of levofloxacin hydrochloride tablets

General Hospital of Ningxia Medical University, Department of Pharmacy, Yinchuan 750004, China;General Hospital of Ningxia Medical University, Division of Clinical pharmacology, Yinchuan 750004, China

摘要: 目的建立高效液相色谱（HPLC）荧光法测定血浆中左氧氟沙星的浓度，研究盐酸左氧氟沙星片在健康人体中的生物等效性。方法采用随机交叉自身对照试验设计，24名健康男性受试者单次口服0.2 g盐酸左氧氟沙星片受试制剂或参比制剂，分别于不同时间点采集肘静脉血，采用HPLC荧光法测定血浆中左氧氟沙星的药物浓度。利用DAS 2.0软件计算药动学参数，评价两制剂的生物等效性。结果受试制剂与参比制剂的主要药动学参数t _1/2、t_max、ρ_max、AUC_0-36和 AUC_0-inf分别为（6.71±0.95）h和（6.60±1.00）h；（0.85±0.30）h 和（0.79±0.28）h ；（2 815.48±513.04）ng/ml和（3 185.59±674.29）ng/ml；（17 157.61±1 949.07）ng·h/ml和（17 425.06±2 447.80）ng·h/ml；（18 324.52±2 019.41）ng·h/ml和（18 540.41±2 523.08）ng·h/ml。两制剂主要药动学参数统计学分析无显著性差异。受试制剂与参比制剂 AUC_0-36、AUC_0-inf 和 ρ_max对数比值的 90%置信区间分别为95.2%~102.5%、96.1%~102.2%和82.8%~94.9%。结论受试制剂与参比制剂具有生物等效性，为生物等效制剂。
- 左氧氟沙星 /
- 高效液相色谱 /
- 生物等效性
Abstract: Objective To develop a HPLC-fluorescence method to determine levofloxacin concentration in plasma for studying bioequivalence of levofloxacin hydrochloride tablet in Chinese healthy volunteers. Methods A single-dose of 0.2 g test or reference preparation was given to 24 healthy volunteers in a randomized crossover study. The concentrations of levofloxacin at different time points were determined by HPLC with fluorescence detection. The pharmacokinetic parameters were calculated using DAS 2.0 software program. Results The main pharmacokinetic parameters of the test and reference preparation,t _1/2、t_max、ρ_max、AUC_0-36 and AUC_0-inf, were respectively (6.71±0.95) h and (6.60±1.00) h,(0.85±0.30) h and (0.79±0.28) h,(2 815.48±513.04) ng/ml and (3 185.59±674.29) ng/ml,(17 157.61±1 949.07) ng·h/ml and (17 425.06±2 447.80) ng·h/ml,(18 324.52±2 019.41) ng·h/ml and (18 540.41±2 523.08) ng·h/ml. The statistical analysis showed that the main pharmacokinetic parameters between test and reference preparations were no significant differences. The 90% confidence interval of test and reference preparations AUC_0-36、AUC_0-inf and ρ_max were 95.2%~102.5%、96.1%~102.2% and 82.8%~94.9%. Conclusion The test and reference preparations were bioequivalent.
- levofloxacin /
- HPLC /
- bioequivalence

[1]	郭小瑞,毕开顺,陈晓辉.盐酸左氧氟沙星胶囊的人体生物等效性研究[J]. 中国现代应用药学杂志,2007,24(2):130-132.
[2]	Zhou ZL, Yang M, Yu XY, et al. A rapid and simple high-performance liquid chromatography method for the determination of human plasma levofloxacin concentration andits application to bioequivalence studies[J].Biomed Chromatogr,2007,21(10):1045-1051.
[3]	钱妍,赵春景,张桂蓉,等.盐酸左氧氟沙星胶囊的人体生物等效性研究 [J].重庆医科大学学报,2007,32(1):59-62.
[4]	谢林利,陈勇川,唐敏,等. 盐酸左氧氟沙星片生物等效性研究[J]. 中国药业,2009,18(16):22-24.

[1]	段禹, 刘爱军. 活血化瘀法治疗血管性痴呆的研究进展 . 药学实践与服务, 2025, 43(4): 151-155, 173. doi: 10.12206/j.issn.2097-2024.202408045
[2]	曹金发, 钟玲, 何苗, 田泾. 炎症性肠病合并心房颤动患者的用药分析与监护 . 药学实践与服务, 2025, 43(): 1-4. doi: 10.12206/j.issn.2097-2024.202403004
[3]	张淑秀, 袁伯川, 杜丽娜, 金义光. 多糖用于放射性核素清除的研究进展 . 药学实践与服务, 2025, 43(): 1-6. doi: 10.12206/j.issn.2097-2024.202405060
[4]	徐璐璐, 刘爱军. 丹参白术方“异病同治”冠心病、血管性痴呆、特发性膜性肾病的网络药理学作用机制研究 . 药学实践与服务, 2025, 43(3): 143-150. doi: 10.12206/j.issn.2097-2024.202312027
[5]	陶宫佳, 陈林林, 宋泽成, 刘梦肖, 王彦. 苦参碱及衍生物的抗炎作用及其机制研究进展 . 药学实践与服务, 2025, 43(4): 163-168, 194. doi: 10.12206/j.issn.2097-2024.202406035
[6]	肖农, 陆诗依, 唐文雅, 居敏俐, 徐刚锋, 杨明华. 中成药微生物计数法前处理的影响因素和优化方法 . 药学实践与服务, 2025, 43(): 1-5. doi: 10.12206/j.issn.2097-2024.202403014
[7]	杨贺英, 罗彩萍, 彭婷, 梁文仪, 沈颂章, 苏娟. 花椒生物碱富集纯化工艺优化及其成分分析 . 药学实践与服务, 2025, 43(2): 75-81. doi: 10.12206/j.issn.2097-2024.202404066
[8]	李惠萍, 陈璐, 张琪金, 黄宝康. 紫苏叶挥发油成分的生物合成、含量测定及生物活性研究进展 . 药学实践与服务, 2025, 43(): 1-6. doi: 10.12206/j.issn.2097-2024.202412058
[9]	舒飞, 孙蕊, 宋凯, 张元林, 闫家铭, 舒丽芯. 粉-液双室袋产品的综合评价 . 药学实践与服务, 2025, 43(2): 92-96. doi: 10.12206/j.issn.2097-2024.202312009
[10]	邵尉, 袁妮, 刘叶, 于飞, 柳莹, 王峰. 丙戊酸钠与左乙拉西坦治疗儿童癫痫病的成本-效果分析 . 药学实践与服务, 2025, 43(): 1-5. doi: 10.12206/j.issn.2097-2024.202408046
[11]	吴海韵, 杨甜, 张弛, 梁文仪, 苏娟. 气相色谱-离子迁移谱技术在中药研究中的应用进展 . 药学实践与服务, 2025, 43(): 1-6. doi: 10.12206/j.issn.2097-2024.202409007
[12]	戴菲菲, 傅翔, 陈琼年, 俞苏纯. 上海某二级医院革兰阴性菌流行特征的回顾性分析 . 药学实践与服务, 2024, 42(12): 528-532. doi: 10.12206/j.issn.2097-2024.202305005
[13]	唐淑慧, 凤美娟, 薛智霞, 鲁桂华. 帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
[14]	桂明珠, 李静, 李志玲. 儿童伏立康唑的血药浓度与CYP2C19、CYP2C9和CYP3A5基因多态性的相关性研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402020
[15]	孙丹倪, 黄勇, 张嘉宝, 王培. 代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049
[16]	王耀振, 徐灿, 吕顺莉, 田泾, 张东炜. 钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 278-284. doi: 10.12206/j.issn.2097-2024.202306040
[17]	张晶晶, 索丽娜, 郑兆红. 89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
[18]	刘丽艳, 余小翠, 孙传铎. 纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
[19]	张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英. 二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
[20]	景凯, 杨慈荣, 张圳, 臧艺蓓, 刘霞. 黄芪甲苷衍生物治疗慢性心力衰竭小鼠的药效评价及作用机制研究 . 药学实践与服务, 2024, 42(5): 190-197. doi: 10.12206/j.issn.2097-2024.202310004

期刊类型引用(0)
其他类型引用(1)

点击查看大图

计量

文章访问数: 4174
HTML全文浏览量: 496
PDF下载量: 723
被引次数: 1

高效液相色谱荧光法测定血浆中左氧氟沙星的浓度及其生物等效性研究

doi: 10.3969/j.issn.1006-0111.2016.05.012

宁夏医科大学总医院, 药剂科, 宁夏银川 750004;宁夏医科大学总医院, 临床药理研究室, 宁夏银川 750004

收稿日期: 2015-02-26
修回日期: 2015-06-10

关键词:

左氧氟沙星 /

高效液相色谱 /

生物等效性

摘要: 目的建立高效液相色谱（HPLC）荧光法测定血浆中左氧氟沙星的浓度，研究盐酸左氧氟沙星片在健康人体中的生物等效性。方法采用随机交叉自身对照试验设计，24名健康男性受试者单次口服0.2 g盐酸左氧氟沙星片受试制剂或参比制剂，分别于不同时间点采集肘静脉血，采用HPLC荧光法测定血浆中左氧氟沙星的药物浓度。利用DAS 2.0软件计算药动学参数，评价两制剂的生物等效性。结果受试制剂与参比制剂的主要药动学参数t _1/2、t_max、ρ_max、AUC_0-36和 AUC_0-inf分别为（6.71±0.95）h和（6.60±1.00）h；（0.85±0.30）h 和（0.79±0.28）h ；（2 815.48±513.04）ng/ml和（3 185.59±674.29）ng/ml；（17 157.61±1 949.07）ng·h/ml和（17 425.06±2 447.80）ng·h/ml；（18 324.52±2 019.41）ng·h/ml和（18 540.41±2 523.08）ng·h/ml。两制剂主要药动学参数统计学分析无显著性差异。受试制剂与参比制剂 AUC_0-36、AUC_0-inf 和 ρ_max对数比值的 90%置信区间分别为95.2%~102.5%、96.1%~102.2%和82.8%~94.9%。结论受试制剂与参比制剂具有生物等效性，为生物等效制剂。

English Abstract

Determination of levofloxacin concentration in plasma of Chinese healthy volunteers by HPLC with fluorescence detection and bioequivalence study of levofloxacin hydrochloride tablets

General Hospital of Ningxia Medical University, Department of Pharmacy, Yinchuan 750004, China;General Hospital of Ningxia Medical University, Division of Clinical pharmacology, Yinchuan 750004, China

Received Date: 2015-02-26
Rev Recd Date: 2015-06-10

Keywords:

levofloxacin /
HPLC /
bioequivalence

Abstract: Objective To develop a HPLC-fluorescence method to determine levofloxacin concentration in plasma for studying bioequivalence of levofloxacin hydrochloride tablet in Chinese healthy volunteers. Methods A single-dose of 0.2 g test or reference preparation was given to 24 healthy volunteers in a randomized crossover study. The concentrations of levofloxacin at different time points were determined by HPLC with fluorescence detection. The pharmacokinetic parameters were calculated using DAS 2.0 software program. Results The main pharmacokinetic parameters of the test and reference preparation,t _1/2、t_max、ρ_max、AUC_0-36 and AUC_0-inf, were respectively (6.71±0.95) h and (6.60±1.00) h,(0.85±0.30) h and (0.79±0.28) h,(2 815.48±513.04) ng/ml and (3 185.59±674.29) ng/ml,(17 157.61±1 949.07) ng·h/ml and (17 425.06±2 447.80) ng·h/ml,(18 324.52±2 019.41) ng·h/ml and (18 540.41±2 523.08) ng·h/ml. The statistical analysis showed that the main pharmacokinetic parameters between test and reference preparations were no significant differences. The 90% confidence interval of test and reference preparations AUC_0-36、AUC_0-inf and ρ_max were 95.2%~102.5%、96.1%~102.2% and 82.8%~94.9%. Conclusion The test and reference preparations were bioequivalent.